A quarter of a century after its founding, Oncorad Group is celebrating 25 years in the rapidly evolving private healthcare market. Established in 2000, the company has gradually carved out a niche with specialized medical services and a measured expansion strategy. However, as the healthcare sector experiences a relentless race to open new facilities, the question looms—can Oncorad remain competitive against market giants like Akdital?
Steady growth in a rapidly changing landscape
Since the opening of its flagship clinic, Le Littoral in Casablanca, Oncorad has grown into a network of seven healthcare facilities spanning Casablanca, Marrakech, Agadir, and Tangier. With new projects underway in Rabat, Nador, and Tetouan, the group aims to reach 30 establishments by 2026. While this expansion is notable, it remains cautious compared to the aggressive growth strategies of its competitors, who are reshaping the industry’s standards at breakneck speed.
In a healthcare market where accessibility is becoming a national priority, Oncorad has focused on delivering high-quality services and embracing technological innovation. The introduction of robotic surgery and telemedicine solutions highlights the group’s commitment to modern healthcare, yet these advanced services remain out of reach for many due to high costs and infrastructural challenges.
A strategy under scrutiny
Despite its ambitions, Oncorad faces structural hurdles that could hinder its progress. The intensifying competition has exposed certain limitations, particularly regarding the diversification of its services and geographical reach. With most of its facilities concentrated in major urban centers, the group struggles to penetrate remote regions where the demand for quality healthcare is pressing.
Moreover, the company’s recent fundraising of 458 million dirhams in 2023 signals a clear commitment to growth. However, the critical question remains: will this financial boost be enough to bridge the gap with market leaders? Oncorad must not only expand but do so swiftly and efficiently to stay relevant.
Akdital: An unrivaled competitor?
In this highly competitive landscape, Akdital has emerged as the undisputed leader. With an aggressive expansion strategy and an extensive nationwide presence, Akdital has successfully captured a significant market share. Its approach, centered on standardized healthcare services and a diversified medical offering, has positioned it as the go-to choice for many patients.
Against such a formidable rival, Oncorad struggles to stand out and establish itself in the public’s consciousness. Despite its focus on innovation and quality, the group remains overshadowed by Akdital’s strong brand recognition and superior financial muscle.
What’s next for Oncorad?
The burning question remains—can Oncorad reinvent itself and offer a compelling alternative model, or will it remain a secondary player in Morocco’s private healthcare sector? To secure its future, the group must accelerate its expansion, enhance accessibility, and find ways to make its cutting-edge services more affordable and widespread.
